Advanced Therapy Medical Products (ATMP) have immense potential to transform the lives of patients with genetic diseases. Repligen partners with developers and manufacturers, providing technology breakthroughs and high impact solutions for plasmid and viral vector development and manufacturing.
As demand for plasmids and viral vectors outpace capacity, a greater than 10-fold and potentially close to 100-fold increase in manufacturing efficiency for the gene therapy reagents is likely required to meet demand that is increasing exponentially.
Repligen solutions aim to meet the needs for optimized processes, higher yields, and improved process quality - setting new standards for modern scalable processes from gene to therapy. Repligen also offers hands-on process and implementation consultation led by recognized Gene Therapy, oncolytic and vaccines industry experts.
Repligen Cell and Gene Therapy
As a thought leader in Gene Therapy bioprocessing, Repligen maintains a state-of-the-art Gene Therapy Applications Center focused on developing internal applications expertise as well as effective collaborations with customers and Gene Therapy leaders.
The Center is staffed by a team of experts in vaccine and viral vector production, purification and analytics.
Meet the Repligen Experts
Sr. Director of Technology, Gene Therapy
Rachel Legmann is a subject matter expert focusing on gene therapy processes in upstream, downstream, analytics and scalability areas. She has over 20 years' experience in scalable biologics and gene therapy manufacturing of therapeutic products, viral vectors and proteins for gene therapy.
Sr. R&D Director, Advanced Bioprocess Applications
René Gantier has 20 years of experience developing production and purification processes for biotherapies. He leads the development of advanced bioprocess applications and technologies with a focus on next-generation cell and gene therapy manufacturing processes.